Develops and sells non-surgical treatments for urothelial (bladder) cancers using a proprietary reverse-thermal gel.
Develops and sells non-surgical treatments for urothelial (bladder) cancers using a proprietary reverse-thermal gel.
Sells through specialty distributors to urology practices and hospitals, which are reimbursed by Medicare and insurers, so reimbursement coding matters. Jelmyto, approved in 2020, carries sales; Zusduri, aimed at a larger group of bladder-cancer patients, is the second product.
Moat: narrow (IP / patents, regulatory licence). Proprietary sustained-release gel formulation applied to an underserved non-surgical bladder cancer niche.
Headquarters: Princeton, New Jersey, US · Founded: 2004 · Employees: 291
Size UroGen Pharma (URGN) is a United States Health Care company (Biotechnology) with a market value of $1.46B, the 1987th largest of 3,085 United States companies the cockpit tracks. Shares closed at $29.79 on 18 Nov 2026.
Performance Over six months the shares fell 1.4%, against -17.0% for the median peer and -2.2% for the United States market (cap-weighted) — 8th highest of 20 in its peer set.
Growth Revenue grew 159.3% over the last twelve months (peer median +24.8%); the operating margin is -12.4% (peer median -56.7%).
Valuation It trades at 16.7× forward earnings against a peer median of 46.4× (3rd cheapest of 6).
Short interest Short interest is 10.4% of the free float (30 Oct 2026).
Next results Next results expected around 18 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $250M | $110M | $90.4M | $82.7M | $64.4M |
| Revenue growth | — | +21% | +9% | +29% | — |
| Gross profit | $229M | $97.3M | $81.5M | $73.4M | $56.7M |
| EBITDA | -$28.2M | -$122M | -$95.6M | -$63.8M | -$77.2M |
| Net income | -$65.8M | -$153M | -$127M | -$102M | -$110M |
| Free cash flow | -$137M | -$163M | -$97.1M | -$76.6M | -$87.8M |
| Capital expenditure | $208,776 | $289,000 | $295,000 | $194,000 | $254,000 |
| Total debt | $196M | $130M | $125M | $100M | $100M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| UroGen Pharma URGN | $1.46B | -1% | +159% | -12% | 16.7× | n/a |
| Merck & MRK | $340B | +23% | +5% | 18% | 16.4× | 8.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | URGN | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -14.9% | -12.7% | 9th lowest of 21 |
| 6-month return | -1.4% | -17.0% | 8th highest of 20 |
| Distance from 52-week high | -41.4% | -45.9% | 8th highest of 21 |
| Revenue growth (TTM) | +159.3% | +24.8% | 6th highest of 18 |
| Operating margin | -12.4% | -56.7% | 9th highest of 19 |
| Forward P/E | 16.7× | 46.4× | 3rd cheapest of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| UroGen Pharma URGN | United States | $1.46B | -1% | +159% | -12% | 16.7× | n/a | n/a |
| Wuhan Healthgen Biotechnology 688765.SS | China | $1.46B | -51% | +90% | -297% | n/a | n/a | n/a |
| Fujian Haixi Pharmaceuticals 2637.HK | Hong Kong | $1.47B | -32% | +25% | 33% | 46.4× | n/a | n/a |
| Mesoblast MSB.AX | Australia | $1.49B | -17% | +556% | -43% | n/a | n/a | n/a |
| Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR | United States | $1.44B | -7% | +13% | -7% | n/a | n/a | n/a |
| Peptron 087010.KS | South Korea | $1.49B | -68% | -13% | -488% | n/a | n/a | n/a |
| Nanjing Vazyme Biotech 688105.SS | China | $1.42B | +25% | +16% | -5% | 137.8× | 39.4% | -2.5% |
| uniQure QURE | United States | $1.42B | -17% | +28% | -1,027% | n/a | n/a | n/a |
| TLC BioSciences 7924.TWO | Taiwan | $1.50B | n/a | n/a | n/a | n/a | n/a | n/a |
| Chengdu Olymvax Biopharmaceuticals 688319.SS | China | $1.51B | -37% | +12% | 8% | n/a | n/a | n/a |
| Absci ABSI | United States | $1.41B | +65% | -47% | -9,155% | n/a | n/a | n/a |
| Korsana Biosciences KRSA | United States | $1.52B | +54% | -64% | -5,277% | n/a | n/a | n/a |
| AnaptysBio ANAB | United States | $1.40B | -22% | +13% | 62% | 4.9× | 0.5% | +25.6% |
| Kailera Therapeutics KLRA | United States | $1.53B | -41% | n/a | n/a | n/a | n/a | n/a |
| Precigen PGEN | United States | $1.53B | 0% | +2,388% | 21% | 7.3× | n/a | n/a |
| Rapport Therapeutics RAPP | United States | $1.39B | -34% | n/a | -838% | n/a | n/a | n/a |
| Nurix Therapeutics NRIX | United States | $1.54B | -14% | +739% | 41% | n/a | n/a | n/a |
| CanSino Biologics 688185.SS | China | $1.38B | 0% | +30% | -4% | 199.3× | n/a | n/a |
| Oncolys BioPharma 4588.T | Japan | $1.37B | +181% | +1,749% | -295% | n/a | n/a | n/a |
| Intellia Therapeutics NTLA | United States | $1.37B | -20% | -8% | -821% | n/a | n/a | n/a |
| Vir Biotechnology VIR | United States | $1.57B | +3% | +1,696% | -70% | n/a | n/a | n/a |